ICER Releases Two Draft Reports on Obeticholic Acid

The Institute for Clinical and Economic Review (ICER) recently released two Draft Evidence Reports assessing the comparative clinical effectiveness and value of obeticholic acid. Learn more about its use for primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH) here. (Source: ICER, 5/25/16)

You might also be interested in:

Addressing the Affordability Crisis of Cell & Gene Therapies 12/16/2020
Key Innovations Coming From The Next Generation of PBM’s 08/12/2020
FDA Rejects Intercept's OCA for NASH 07/13/2020
What Are The Recent Top 4 Innovative Consolidations and… 08/26/2020
[Book Release] Value-Based Drug Pricing Guide on Flawed $500… 03/10/2021
What Does $11M in Donations to Congress Buy Pharma? 08/12/2020
The Journal of Clinical Pathways Issues Call for Papers 04/16/2021